|
|
|
|
|
|||||||
|
Session 74
Poster Session
Antiretroviral Chemotherapy: Miscellaneous Topics 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 548-T. | Early Intensification with Abacavir in Subjects at High Risk for Incomplete Suppression J. A. Bartlett*1, P. Tebas2, R. Bassett3, W. Huang3, D. Kuritzkes4, and R. Reisler5 for the ACTG A5064 Study Team 1Duke Univ. Med. Ctr., Durham, NC; 2Washington Univ., St. Louis, MO; 3SDAC Harvard Sch. of Publ. Hlth., Boston, MA, USA; 4Univ. of Colorado, Denver; and 5NIAID, NIH, Bethesda, MD
| ||
| 549-T. | The Efficacy, Safety, and Immunological Changes of qd Saquinavir-Soft Gel Capsules 1600 mg /Ritonavir 100 mg plus Dual Nucleosides in Patients Who Had an Undetectable Viral Load after 3 Years of Treatment P. Cardiello*1,2, P. Srasuebkul1, E. Hassink1,2, A. Mahanontharit1, T. Samor1, W. Worarien1, K. Ruxrungtham1,3, D. A. Cooper4, J. Lange2, and P. Phanuphak1 1HIVNAT and 2IATEC, Amsterdam, The Netherlands; 3Chulalongkorn Univ., Bangkok; and 4NCHECR, Univ. of New South Wales, Australia
| ||
| 550-T. | Durability of Ritonavir (RTV) plus Saquinavir (SQV) Dual Protease Inhibitor Therapy in HIV Infection: 5-Year Follow-Up D. W. Cameron *1, J. B. Angel1, J. Ryan2, P. Jiang1, R. Rode*2, C. Farthing3, C. Cohen4, J. Mellors5, D. Poretz6, M. Markowitz7, D. Ho7, D. McMahon5, D. Drennan8, T. Seidler2, E. Sun2, and A. J. Japour2 1Univ. of Ottawa and Ottawa Hosp., ON, Canada; 2Abbott Labs, Abbot Park, IL; 3AIDS Healthcare, Los Angeles, CA; 4Comm. Res. Initiative, Boston, MA; 5Univ. of Pittsburgh, PA; 6Infectious Diseases Physicians, Annandale, VA; 7Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; and 8Davies Med. Ctr., San Francisco, CA
| ||
| 551-T. | Analysis of Virological Efficacy in Randomised Trials of Antiretroviral Regimens: Drawbacks of No HIV-RNA Measurements after Premature Interruption of Therapy O. Kirk*, M. Law, C. Pedersen, R. M. Gulick, G. Moyle, A. N. Phillips, and J. D. Lundgren EuroSIDA Co-ord. Ctr., Hvidovre, Denmark
|
